"Vertex's Non-Opioid Painkiller Triumphs in Midstage Trial, Shares Surge"
TL;DR
Shares of Vertex Pharmaceuticals surged after positive midstage trial results showed that the company's painkiller, VX-548, significantly reduced pain in diabetes patients with chronic nerve conditions. The drug aims to provide strong pain relief without the addictive potential of opioids, and analysts believe it could become a blockbuster drug with annual sales exceeding $1 billion. Vertex is now working to advance the drug to a late-stage trial and is also testing it for acute pain. The stock rose 10% following the trial data release and has gained nearly 40% this year.
Topics:businesshealthcare#chronic-nerve-pain#healthcare#midstage-trial#opioids#painkiller#vertex-pharmaceuticals
- Vertex shares pop after nonopioid painkiller posts positive midstage trial results CNBC
- Vertex Pharmaceuticals Jumps on Pain Medication Success: How to Play It RealMoney
- Vertex Rallies, Flashes Bullish Signal On Phase 2 Results For Opioid Alternative Investor's Business Daily
- Vertex passes neuropathic pain test, teeing up pivotal trials in pursuit of blockbuster opportunity FierceBiotech
- Vertex's non-opioid drug reduces nerve pain in trial, shares hit record high Reuters.com
Want the full story? Read the original reporting
Read on CNBC